ROCK HILL, S.C. and LEUVEN,
Belgium, Oct. 23, 2019 /PRNewswire/ -- Today, 3D
Systems (NYSE: DDD) and Antleron are announcing a
collaboration, intended to play a pivotal role in advancing and
accelerating breakthroughs in the biomedical industry. Bringing
together two industry pioneers – 3D Systems for 3D printing
technologies and healthcare expertise, and Antleron
for leadership and innovation in the development of
regenerative products and personalized patient care - the companies
will collaborate to support Antleron's development of bioprinting
solutions utilizing 3D Systems' printing technologies.
Antleron has created an R&D facility at their headquarters
in Leuven, Belgium - a location
known as an incubator for medical and life science innovation,
including regenerative medicine, to support and validate customer
projects in the field of 3D bioprinting. Antleron's 'living therapy
factory' merges cells, biomaterials, biologics, bioreactors
and 3D Systems printers to accelerate the engineering of living
therapies. Using quality-by-design and artificial intelligence the
Antleron multidisciplinary specialists translate these core
technologies into pioneering workflows that turn cells into
therapies.
The 3D Systems/Antleron relationship addresses solutions for
medical device and advanced therapy medicinal product (ATMP)
applications, incorporating a variety of innovative technologies
that are of benefit to biomedical manufacturing process, beginning
with 3D Systems' ProJet® MJP 2500 and Figure
4® 3D printers and existing portfolio of 21
biocompatible, USP Class VI materials; 3D
Sprint® and 3DXpert® software, and
post-processing equipment and processes. The goal is to establish a
flexible, scalable Digital Factory approach, built on modular,
closed parametric processes which include digital monitoring and
quality control for risk mitigation. An example is to advance the
way cells and tissues are grown to enable the transition from a
static 2D to bioreactor-based 3D cell culture. This can lead to new
ways to manufacture functionalized medical implants, vaccines, cell
therapies, and living tissues.
According to Antleron CEO, Jan
Schrooten, "The vision of Antleron is to sustainably bring
living therapies into the clinic. 3D printing is key to this
endeavor, and we are eager to collaborate with 3D Systems and its
experts. I look forward to the pioneering solutions we'll be able
to achieve to elevate the efficacy of bioprinting and extend its
biomedical application reach."
"3D Systems is excited about working with Antleron as they
explore bioprinting, and especially their capability to develop
end-to-end solutions utilizing the 3D Systems' state of the art
printing platforms and materials," said Chuck Hull, co-founder and chief technology
officer, 3D Systems. "As we look to the future, bioprinting and
regenerative medicine are large opportunities for 3D printing, and
we look forward to expanding the role 3D Systems will play in these
exciting fields."
At Formnext 2019 to be held November
19-22, 3D Systems (booth D03, hall 12.1) and Antleron will
exhibit for the first time what is in store for next-generation
medical applications with the ProJet MJP 2500 printer and
VisiJet® materials.
Forward-Looking Statements
Certain statements made in
this release by or in reference to 3D Systems that are not
statements of historical or current facts are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, performance or achievements of the company to be
materially different from historical results or from any future
results or projections expressed or implied by such forward-looking
statements. In many cases, forward looking statements can be
identified by terms such as "believes," "belief," "expects," "may,"
"will," "estimates," "intends," "anticipates" or "plans" or the
negative of these terms or other comparable terminology.
Forward-looking statements are based upon management's beliefs,
assumptions and current expectations and may include comments as to
the company's beliefs and expectations as to future events and
trends affecting its business and are necessarily subject to
uncertainties, many of which are outside the control of the
company. The factors described under the headings "Forward-Looking
Statements" and "Risk Factors" in 3D Systems' periodic filings with
the U.S. Securities and Exchange Commission, as well as other
factors, could cause actual results to differ materially from those
reflected or predicted in forward-looking statements. Although
management believes that the expectations reflected in the
forward-looking statements are reasonable, forward-looking
statements are not, and should not be relied upon as a guarantee of
future performance or results, nor will they necessarily prove to
be accurate indications of the times at which such performance or
results will be achieved. The forward-looking statements included
are made only as the date of the statement. 3D Systems undertakes
no obligation to update or review any forward-looking statements
made by management or on its behalf, whether as a result of future
developments, subsequent events or circumstances or otherwise.
About 3D Systems
More than 30 years ago, 3D Systems
brought the innovation of 3D printing to the manufacturing
industry. Today, as the leading AM solutions company, it empowers
manufacturers to create products and business models never before
possible through transformed workflows. This is achieved with the
Company's best-of-breed digital manufacturing ecosystem - comprised
of plastic and metal 3D printers, print materials, on-demand
manufacturing services and a portfolio of end-to-end manufacturing
software. Each solution is powered by the expertise of the
company's application engineers who collaborate with customers to
transform manufacturing environments. 3D Systems' solutions address
a variety of advanced applications for prototyping through
production in markets such as aerospace, automotive, medical,
dental and consumer goods. More information on the company is
available at www.3dsystems.com.
About Antleron
Antleron is a young R&D company on
a mission to enable personalized manufacturing 4.0 in the domain of
advanced therapies. The company's nimble team is revolutionizing
medicine by merging the potential of cells, biomaterials,
biologics, 3D printing and bioreactors to accelerate the
engineering of living therapies - empowering patients with fully
personalized, regenerative care. Antleron translates core
technologies including additive manufacturing (AM),
quality-by-design and artificial intelligence into pioneering
workflows that turn cells into living therapies to eventually make
organ manufacturing a reality. To support its mission, Antleron's
business philosophy is to create sustainable ventures that bring
living, personalized therapies from idea to patient through risk
& reward sharing partnerships. From the company's headquarters
in Belgium, Antleron operates at
the cutting edge between life sciences and technology within
Europe's leading biotech
ecosystem. More information on the company is available at
www.antleron.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/3d-systems-and-antleron-collaborating-to-accelerate-3d-printing-biomedical-breakthroughs-300943688.html
SOURCE 3D Systems